| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Property and equipment, net | 102 | |||
| Non-current prepaid expenses and other assets | 241 | |||
| Operating lease right-of-use assets | 32 | |||
| Total non-current assets | 375 | |||
| Prepaid and other current assets | 4,696 | |||
| Investment in marketable securities | 17,600 | |||
| Cash and cash equivalents | 22,047 | |||
| Total current assets | 44,343 | |||
| Total assets | 44,718 | |||
| Other current liabilities | 0 | |||
| Operating lease liabilities | 25 | |||
| Employee related obligations | 819 | |||
| Accrued expenses | 3,578 | |||
| Trade payables | 1,414 | |||
| Total current liabilities | 5,836 | |||
| Total liabilities | 5,836 | |||
| Accumulated deficit | -745,536 | |||
| Common stock 0.0001 par value 150,000,000 shares authorized at june30, 2025 and december31, 2024 19,773,784 and 14,830,013 shares issued and outstanding at june30, 2025 and december31, 2024, respectively | 2 | |||
| Additional paid-in capital | 784,418 | |||
| Accumulated other comprehensive (loss) income | -2 | |||
| Total stockholders' equity | 38,882 | |||
| Total liabilities and stockholders equity | 44,718 | |||
VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Inc. (VYNE)